Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00382148 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Minor Enrollment target: 10 to 11 Primary completion date: Jun 2008 to Jun 28, 2008 · Completion date: Jun 28, 2008 · Secondary endpoints: details revised at 1 of 3 entriesv7 Show all 4 changesShow less
    • Primary completion date: Jun 2008 to Jun 28, 2008
    • Completion date: Jun 28, 2008
    • Secondary endpoints: details revised at 1 of 3 entries
  2. Notable Results first posted: Dec 15, 2009 Enrollment target: estimated 25 to confirmed 10 · Primary completion date: Jun 2008 · Completion date: Jun 2008 to not stated · 2 morev6 Show all 6 changesShow less
    • Enrollment target: estimated 25 to confirmed 10
    • Primary completion date: Jun 2008
    • Completion date: Jun 2008 to not stated
    • Secondary endpoints: 4 to 3
    • Primary endpoint revised

    See this version in full on ClinicalTrials.gov ↗

  3. Minor Trial status: Active, Not Recruiting to Completed Study completion date changed from estimate of Nov 2008 to Jun 2008v5 Show all 2 changesShow less
    • Study completion date changed from estimate of Nov 2008 to Jun 2008
  4. Minor Completion date: Nov 2008 Start date: Oct 2006 to Nov 2006 · Interventions: Xolair (omalizumab) (Drug) to omalizumab (Drug) · Eligibility criteria revised · 2 morev4 Show all 6 changesShow less
    • Start date: Oct 2006 to Nov 2006
    • Interventions: Xolair (omalizumab) (Drug) to omalizumab (Drug)
    • Eligibility criteria revised
    • Secondary endpoints revised (4)
    • Study arms: 0 to 1

    See this version in full on ClinicalTrials.gov ↗

  5. Notable Primary endpoint revised Trial status: Recruiting to Active, Not Recruiting · Study sites: 1 to 0 · Eligibility criteria revised · 1 morev3 Show all 5 changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 1 to 0
    • Eligibility criteria revised
    • Secondary endpoints revised (4)

    See this version in full on ClinicalTrials.gov ↗

  6. Notable Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show all 2 changesShow less
    • Study sites: 0 to 1
  7. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
366 trials monitored
See 33 trials at risk
This is a Phase IIb, multicenter, open-label study available to active (Xolair) and control (placebo) subjects who have completed their final visit (or early termination visit, if applicable) for Study Q2788g, who meet the eligibility criteria of this study, and who provide consent to participate in this study.
Trial Details
NCT Number NCT00382148
Lead Sponsor Genentech, Inc.
Conditions Peanut Hypersensitivity
Enrollment 11 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov